Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022 Presentation to review historic issues related to glaucoma therapies and how these may be addressed…

Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

April 19, 2022 at 8:00 AM EDT EYENOVIA ANNOUNCES POSTER PRESENTATION AT THE 2022 AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose…

Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions

Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Eyenovia,…

Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

No additional clinical work required; NDA resubmission anticipated in Q3 2022 NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose…

Eyenovia Announces Changes to the Board of Directors

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced changes to its Board of Directors. …

Eyenovia Reports Third Quarter 2021 Financial Results

Eyenovia Reports Third Quarter 2021 Financial Results On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022 Current cash resources anticipated…

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator @AAO 2021 Meeting

Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics NEW YORK—November 8, 2021—Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic…

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022  Presbyopia represents a multi-billion-dollar market…

Eyenovia Announces Reclassification of MydCombi™ as Drug-Device Combination Product by FDA

Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review of all drugs that are in delivery systems, including eye dropper bottles  Company received Complete Response Letter with additional requests and is preparing necessary…